Table 1: Ongoing Clinical trials in MCC.

NCT Identifier Title Phase Treatment
NCT02584829 Localized Radiation Therapy or Recombinant Interferon beta and Avelumab with or without Cellular Adoptive Immunotherapy in Treating Patients with Metastatic Merkel Cell Carcinoma 1/2 Aveluma, Merkel cell polyomavirus TAg- specific polyclonal autologous CD8-positive T cells, Interferon beta, RT
NCT02643303 A Phase 1/2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab plus Poly ICLC in Subjects with Advanced, Measurable, Biopsy-Accessible Cancers 1/2 Durvalumab, Tremelimumab, Poly ICLC
NCT 02488759 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-Associated Tumors (CheckMate 358) 1/2 Nivolumab, Ipilimumab, BMS-986016, Daratumumab
NCT 03071406 Randomized Study of Nivolumab plus Ipilimumab +/- SBRT for Metastatic Merkel Cell Carcinoma 2 Nivolumab, Ipilimumab, SBRT
NCT02196961 Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma with Immune Checkpoint Blocking Antibodies versus Observation (ADMEC-O) 2 Ipilimumab, Nivolumab
NCT03271372 Adjuvant Avelumab in Merkel Cell Cancer (ADAM) 3 Avelumab